| Name | Title | Contact Details |
|---|
HyGreen is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inteprod LLC is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Interim HealthCare Inc., founded in 1966, is a leading national franchisor of home care, hospice and healthcare staffing. It is part of Caring Brands International which also includes UK-based Bluebird Care and Australia-based Just Better Care, both well-known franchise brands in their countries. With more than 530 franchise locations in seven countries Caring Brands International is a global health care leader. Interim HealthCare in the United States is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service. Franchisees employ nurses, therapists, aides, companions and other healthcare professionals who provide 25 million hours of home care service to 190,000 people each year, meeting a variety of home health, senior care, hospice, palliative care, pediatric care and healthcare staffing needs.
Grant and Associates is a Olympia, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.